3. Subjects may be taking ManNAc at the time of their enrollment, but must be willing to stop treatment with ManNAc, sialic acid (SA), intravenous immunoglobulin (IVIG), and/or other supplements containing SA (e.g., St John s wort, sialyllactose) after the screening assessment and must be willing to remain off treatment for the duration of the study.